Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Terminated × Muscle-invasive Bladder Cancer × Clear all

Phase

Status

Not yet recruiting 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 354 Carcinoma, Non-Small-Cell Lung 230 Prostatic Neoplasms 178 Neoplasms 170 Neoplasm Metastasis 158 Melanoma 134 Leukemia, Myeloid, Acute 128 Colorectal Neoplasms 125 Multiple Myeloma 124 Leukemia 106 Lung Neoplasms 104 Lymphoma 102 Pancreatic Neoplasms 95 Recurrence 94 Leukemia, Lymphocytic, Chronic, B-Cell 93 Lymphoma, Non-Hodgkin 91 Carcinoma, Renal Cell 87 Ovarian Neoplasms 85 Myelodysplastic Syndromes 78 Brain Neoplasms 76 Precursor Cell Lymphoblastic Leukemia-Lymphoma 73 Lymphoma, Follicular 72 Glioblastoma 71 Lymphoma, Large B-Cell, Diffuse 70 Carcinoma, Hepatocellular 66 Head and Neck Neoplasms 64 Squamous Cell Carcinoma of Head and Neck 62 Urinary Bladder Neoplasms 53 Hodgkin Disease 51 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 49

Interventions

tremelimumab 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03234153 2020-06-17

NITIMIB

Insel Gruppe AG, University Hospital Bern

Phase 2 Terminated

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡